



The MANGO Study

# Measuring Adverse Pregnancy and Newborn Congenital Outcomes (MANGO) Study:

**A hospital based-surveillance program for adverse pregnancy  
and birth outcomes in a resource-limited setting**

Audrey Chepkemoi, MBChB, Mmed, Neonatologist

Moi Teaching and Referral Hospital, Eldoret, Kenya



East Africa

**leDEE**  
INTERNATIONAL EPIDEMIOLOGY  
DATABASES TO EVALUATE AIDS



INDIANA UNIVERSITY

# Background



The MANGO Study

**Purpose:** MANGO is a pharmacovigilance study to assess pregnancy exposures and outcomes : examining the impact of HIV infection and ART exposure at conception and during pregnancy


**Study design:** mixed prospective and retrospective cohort

**Implementation Period:** Sept 2020 - Present

**Site:** Moi Teaching and Referral Hospital (MTRH), Kenya



# Methods



# Education / Training and QI program

The surveillance also involved :

a) **Healthcare worker training on:**

- comprehensive newborn surface exam
- birth defect identification
- **Improved documentation .**

• Training were done through :

- Recurring in-person and zoom meetings in work areas
- Structured Nurse Training Course
  - Offered CME credits

b) **Quality Improvement (QI) program in collaboration with hospital**

Training session on surface exam and birth defects



# Enhanced NBSE and congenital abnormality documentation



The MANGO Study

Delivery record "Pink Form" with limited documentation space

REPORT ON LABOUR DATE: \_\_\_\_\_

Labour	Bagit	Membrane ruptured	Foetal position	Baby Size	Placenta position	Amount of Loin
--------	-------	-------------------	-----------------	-----------	-------------------	----------------

DRUGS ORDERED DURING LABOUR INCLUDING 3<sup>rd</sup> STAGE

Date	Time	Drug	Dose	Given by	Remarks
------	------	------	------	----------	---------

**BURSTION OF LABOUR**

1st Stage	
2nd Stage	
3rd Stage	
Total Time	

**TYPE OF DELIVERY**

Delivered By	
Method	
Position	
Page	

**AFTER DELIVERY**

Condition of Mother	Condition of Baby
TPR	Sex
Fundus	Weight
Loss P.V.	Abnormalities
B/P	Remarks
Weight of Placenta	

Then: Now:

**DELIVERY**

Condition of Baby

Sex

Weight

Abnormalities

Remarks

An ISO 9001: 2015 Certified Hospital  
**MOI TEACHING AND REFERRAL HOSPITAL**

**NEWBORN SURFACE EXAMINATION AND DOCUMENTATION FORM**

Mother's Name..... HIV Status.....  
 Hospital Number..... CCC Number.....

Neonatal Data			
Time Of Delivery		Date of delivery	
Gender			
<b>Normal Ranges (For Term baby = &gt;37 weeks Gestation)</b>			
Birth Weight		≥ 2.5 < 4	
Head circumference		35 ± 2	
Birth Length		50 ± 2	
Foot Length		7cm ± 1	

Infant Physical Examination			
	Normal	Anomaly Present	Describe any anomaly identified (include side involved, location, size, extend, laterality, covering, extrusion of any organ, mobility)
Head			
Eyes			
Ears			
Nose and Mouth			
Neck and Clavicles			
Chest and Lungs			
Abdomen and Cord			
Genitalia			
Anus			
Back and Spine			
Limbs and Hip			
Skin			
Neonatal Reflexes			


Remarks	
Give baby to mother	
Admit to NBU	
Discharge through Clinic (Name of clinic)	

Name \_\_\_\_\_ Signature \_\_\_\_\_

# Some results from Audit-Based for Practice Improvement of Newborn Assessment

At baseline in 2021 of 8084 infants delivered, 1553(19.2%) infants had completed documentation of the NBSE from baseline audit

## Results after 1 year of intervention



**Currently – SVD NBSE is at 95-98% among SVD deliveries**

Characteristics of the MANGO cohort at delivery, October 2020 to September 2023.

Major congenital abnormality prevalence of 0.74% as of 2023

Indicator	MANGO N=24,205	Kenya Aggregate Data (Ref.)
<b>Maternal age at delivery (years), n (%)</b>		
<20	1,947 (8.0)	13.0% <sup>a</sup>
<b>20-34</b>	<b>18,315 (75.7)</b>	<b>74.1%<sup>a</sup></b>
35-49	3,892 (16.1)	12.9% <sup>a</sup>
Missing	51 (0.2)	--
<b>Women living with HIV, n (%)</b>	<b>1,084 (4.5)</b>	<b>5.2%<sup>b</sup></b>
Transfer in for delivery, n (%)	1,754 (7.2)	n/a
Caesarian section delivery, n (%)	5,641 (23.3)	23.8% <sup>c</sup>
Missing	14 (0.06)	
<b>Stillbirth, n (%)</b>	<b>627 (2.6)</b>	<b>1.6%<sup>d</sup></b>
<b>Per 1000 births</b>	<b>25.9</b>	<b>15.8</b>
Missing	16 (0.07)	
Premature birth (<37 weeks), n (%)	4,161 (17.7) <sup>e</sup>	12.3% <sup>d</sup>
Low birth weight (<2.5 kg), n (%)	3,643 (15.5) <sup>e</sup>	10.0% <sup>f</sup>
<b>Major congenital abnormality, n (%)<sup>g</sup></b>		
<b>C1 (n=839)</b>	<b>4 (0.48, 95% CI 0.13-1.22)</b>	--
<b>C2 (n=23,004)</b>	<b>175 (0.76, 95% CI 0.65-0.88)</b>	--
<b>Total (n=24,205)</b>	<b>179 (0.74, 0.63-0.85)</b>	--
<b>Total per 10,000 births</b>		--
<b>C1</b>	<b>47.7 (95% CI 13-122)</b>	--
<b>C2</b>	<b>76.1 (95% CI 65-88)</b>	--
<b>Total</b>	<b>73.9 (95% CI 63-85)</b>	--



# All abnormalities ( minor and major as of september 2024 )

Abnromality	Total	Percentage n=27001
Extra digit	189	0.7%
Arm and leg	130	0.5%
Head and neck	115	0.4%
Toes and fingers	113	0.4%
Others	104	0.4%
Hip and genitalia	69	0.2%
Abdomenal and anal	64	64%
Hydrocephalus	40	0.1%
Mouth , lip and palate	38	0.1%
Spine	27	0.1%
Skull defect	24	0.1%
Skin	12	0.04%
Chest	7	0.03%
<b>Total</b>	<b>932</b>	<b>3.5%</b>

**Prevalence  
major CA :  
1% as of  
September 2024**

**Among infants born to women enrolled in C1, community-based surface examination identified some cases in which a major Cas was not reported by the mother via phone contact.**



# Vital status at birth of neonates with major CA and results of the follow-up

October 2020 to  
September 2024

N= 277

Vita status at birth

live birth 261 (94.2%)

Fresh stillbirth 9 (3.2%)


Macerated  
stillbirth. 6 (2.2%)

## Follow- up results : Among the live births

- ❖ At 1 month , 248 eligible infants
  - 24 (8.7%) were already deceased before follow- up
  - 24 (8.7%) had died
  - 18 (6.5%) was unreachable by phone.
- ❖ At 6 months, 211.eligible infants,
  - 4(1.7%) had died
  - 42 (18.0%) were unreachable.
- ❖ At 1 year : 203 (85.7%) eligible
  - 7 (3.0%) had died
  - 62 (26.2%) were unreachable.

Majority of the patient with CA died within 1 month of life 48(17.4%)

# "Diagnosis Done, Surveillance Ongoing—What's the Next Step?"



NICHD Supplement grant to East Africa leDEA:

**Study title: Development of a user-centered model of service delivery for families of infants with major congenital abnormalities in Kenya**

# Development of a user-centered model of service delivery for families of infants with major congenital abnormalities in Kenya

## Objectives

- **Aim 1.** Explore community perceptions, lived experiences and care needs of families with infants diagnosed with congenital abnormalities in resource-limited settings.
- **Aim 2.** Develop a service delivery model optimized to meet the needs of families with infants diagnosed with congenital abnormalities in resource-limited settings.

# Study design – Human centered - design


## For the *discover* phase,

We conducted **in-depth interviews with 31 parents** of infants with major CAs delivered at MTRH to understand their experiences and care needs.

## For the *define* and *develop* phases,

We conducted **HCD workshops with 19 healthcare providers** involved in the care of children with CAs at MTRH and **15 caregivers( parents)**

# Social-ecological model of factors influencing care needs of families of infants with major congenital abnormalities



Domain	Themes	Sub- themes
Individual domain	<b>Psychological and emotional impact,</b> <b>Stigma</b> <b>Financial challenges</b>	<b>Initial Reactions</b> :fear, sadness, anxiety. <b>Self-Blame and denial</b> , Maladaptation <b>Need for health Professional support</b> Importance of health insurance
Peer and family domain	<b>Psychological and emotional impact on the family</b> <b>Stigma</b> <b>Impact of family financial</b> <b>Partner involvement and shared responsibility</b>	Importance of family therapy and counselling <b>Role sibling ,extended family and community</b>
Health care domain	Early diagnosis Support services Health education Integrated care clinic Post discharge care	Affordability of specialized services Counselling and child life services Training of health care providers Crowding and long queues Multidiplinary approach
Community and societal domain	<b>Community perceptions</b> Stigma Community support	Health education

# Example quotes from participants



The MANGO Study

<b>Sub themes</b>	<b>Quotes</b>
<b>Psychological and emotional impact</b>	"I almost had a heart attack and I was very shocked. I used to arrive to the hospital sweating, at times I forgot what I was coming to do."
<b>Poverty</b>	"I had to stop due to financial limitations."
<b>Community and interpersonal stigma</b>	"I saw that I would be laughed at by people in the area, and then I came to know that is what made the father deny the child. Till today I don't know where he is."
<b>Need for support and early diagnosis</b>	"If the child is diagnosed early, you can get help early." "If I knew before, I could have aborted." "It is like you have given birth to this child, you have been left to go and struggle on your own, but ... they should explain to you ...they don't tell you anything. "

# Next steps



The MANGO Study

1. Analyses of associations between HIV/ART exposure and adverse pregnancy/newborn outcomes
  - Mango-Kenya data
  - Bi-regional analysis of Kenya and South Africa data
2. Hospital transition to EMR
  - New challenges in improving surveillance , documentation and EMR utilization
  - Cleaning, harmonizing antenatal and perinatal EMR data
3. Interventions to provide more holistic care for families of infant with major congenital abnormalities



# Summary

- ✓ Surveillance for CA requires a comprehensive approach
- ✓ Majority of infants with CA die in the neonatal period
- ✓ community-based surface examination and follow-up is feasible and can strength the surveillance process .

## ***Beyond the numbers***

- ✓ Families with children born with CAs, face multifaceted challenges that require a comprehensive approach to address them .



The MANGO Study

# Acknowledgements

- Mango study team

- Rena Patel, Edwin Were, John Humphrey Molly McPheron, Steve Brown, Harold Koreman, James Carlucci, Megan McHenry, Caitlin Bernard, Laura Oyiengo, Beatrice Ochieng, Winnie Matelong, MaryLydia Kiano, Caroline Kerich, Beverly Musick, and others
- Constantin T. Yiannoutsos, Kara Wools-Kaloustian (East Africa leDEA co-PIs)

## East Africa leDEA consortium:

- Yee Yee Kuhn, Cosmas Apaka, Samuel Ayaya, Lameck Diero, Aggrey Semeere

## Clinical staff at Moi Teaching and Referral Hospital



INDIANA UNIVERSITY



The MANGO Study



**UAB MEDICINE**

The University of Alabama at Birmingham

REPUBLIC OF KENYA



MINISTRY OF HEALTH

